Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase NA 1

Status

Not yet recruiting 3Recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Head & Neck 4

Conditions

Squamous Cell Carcinoma of Head and Neck 30Oropharyngeal Neoplasms 21Nasopharyngeal Carcinoma 16Head and Neck Neoplasms 13Prostatic Neoplasms 12Laryngeal Neoplasms 9Carcinoma, Non-Small-Cell Lung 9Carcinoma, Squamous Cell 8Carcinoma 8Breast Neoplasms 8Rectal Neoplasms 7Mouth Neoplasms 7Hypopharyngeal Neoplasms 7Glioma 6Glioblastoma 6Uterine Cervical Neoplasms 5Papillomavirus Infections 5Esophageal Neoplasms 5Urinary Bladder Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Nasopharyngeal Neoplasms 4Astrocytoma 4Mesothelioma, Malignant 3Lymphatic Metastasis 3Lung Neoplasms 3Leukemia, Myeloid, Acute 3Endometrial Neoplasms 3Brain Neoplasms 3Tumor Virus Infections 2Tongue Neoplasms 2

Interventions

Cisplatin 7Gemcitabine 6pembrolizumab 4Radiotherapy, Intensity-Modulated 4toripalimab 2Bevacizumab 2tocilizumab 1tislelizumab 1spartalizumab 1penpulimab 1atezolizumab 1Vitamin D 1Tablets 1Surveys and Questionnaires 1Phantoms, Imaging 1Oral Hygiene 1Observation 1Magnetic Resonance Spectroscopy 1Immunotherapy 1Immunohistochemistry 1Immunoglobulin G 1Fluorouracil 1Disulfides 1Dexamethasone 1Chemoradiotherapy 1Cetuximab 1Carboplatin 1Capecitabine 1Blood Specimen Collection 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Nasopharyngeal Neoplasms × Radiotherapy, Intensity-Modulated × 1 year × Clear all
NCT06682442 2026-05-01

Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma

University of California, San Francisco

Phase NA Recruiting
66 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Epstein-Barr Virus Infections

NCT07524413 2026-04-13

Becotatug Vedotin (MRG003) With PD-1 Blockade and Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma

Sun Yat-sen University

Phase 3 Not yet recruiting
514 enrolled
Head & Neck

Nasopharyngeal Neoplasms

NCT07385079 2026-02-03

Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma

Sun Yat-sen University

Phase 3 Not yet recruiting
412 enrolled
Head & Neck

Nasopharyngeal Neoplasms

NCT07373990 2026-01-28

Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma

Sun Yat-sen University

Phase 3 Not yet recruiting
418 enrolled
Head & Neck

Nasopharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡